Switch theme
Sign up to access all valuation multiples
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
2006
9
Last FY Revenue $1.6M
Last FY EBITDA -$2.4M
$15.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Enorama Pharma achieved revenue of $1.6M and an EBITDA of -$2.4M.
Enorama Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Enorama Pharma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $1.6M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.4M | XXX | XXX | XXX |
| Gross Margin | XXX | 23% | XXX | XXX | XXX |
| EBITDA | XXX | -$2.4M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -146% | XXX | XXX | XXX |
| EBIT | XXX | -$4.9M | XXX | XXX | XXX |
| EBIT Margin | XXX | -302% | XXX | XXX | XXX |
| Net Profit | XXX | -$4.5M | XXX | XXX | XXX |
| Net Margin | XXX | -278% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Enorama Pharma's stock price is SEK 3 (or $0).
Enorama Pharma has current market cap of SEK 157M (or $16.2M), and EV of SEK 152M (or $15.7M).
See Enorama Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15.7M | $16.2M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Enorama Pharma has market cap of $16.2M and EV of $15.7M.
Enorama Pharma's trades at 9.6x EV/Revenue multiple, and -6.6x EV/EBITDA.
Equity research analysts estimate Enorama Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Enorama Pharma's P/E ratio is not available.
See valuation multiples for Enorama Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $16.2M | XXX | $16.2M | XXX | XXX | XXX |
| EV (current) | $15.7M | XXX | $15.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 9.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -6.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -3.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -3.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEnorama Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.6M for the same period.
Enorama Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Enorama Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Enorama Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -146% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 325% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Enorama Pharma acquired XXX companies to date.
Last acquisition by Enorama Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Enorama Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Enorama Pharma founded? | Enorama Pharma was founded in 2006. |
| Where is Enorama Pharma headquartered? | Enorama Pharma is headquartered in Sweden. |
| How many employees does Enorama Pharma have? | As of today, Enorama Pharma has 9 employees. |
| Is Enorama Pharma publicy listed? | Yes, Enorama Pharma is a public company listed on STO. |
| What is the stock symbol of Enorama Pharma? | Enorama Pharma trades under ERMA ticker. |
| When did Enorama Pharma go public? | Enorama Pharma went public in 2016. |
| Who are competitors of Enorama Pharma? | Similar companies to Enorama Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Enorama Pharma? | Enorama Pharma's current market cap is $16.2M |
| Is Enorama Pharma profitable? | Yes, Enorama Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
